Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia

This study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with incoBoNT/A injections. Physicians assessed treatment efficacy using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at the baseline visit, week 12 and 48. Patients rated quality of life of CD with the Craniocervical Dystonia Questionnaire (CDQ-24). Titres of neutralizing antibodies(NAB) were determined at start of the study and after 48 weeks. All patients had experienced significant and progressive worsening of symptoms in the last 6 months of previous BoNT treatment. Repeated incoBoNT/A injections resulted in a significant reduction in mean TWSTRS at week 12 and 48. Patients' rating of quality of life was highly correlated with TWSTRS but did not change significantly over 48 weeks. During the 48 weeks -period of incoBoNT/A treatment NAB titres decreased in 32.2%, did not change in 45.2%, and only increased in 22.6% of the patients. Thus, repeated treatment with the low dose of 200 MU incoBoNT/A over 48 weeks provided a beneficial clinical long-term effect in PSTF and did not booster titres of NAB.

Download Full-text

Affective disorders and quality of life in patients with cervical dystonia regularly treated with botulinum toxin

Journal of the Neurological Sciences ◽

10.1016/j.jns.2021.119543 ◽

2021 ◽

Vol 429 ◽

pp. 119543

Author(s):

Robert Ibatullin ◽

Mansur Kutlubaev ◽

Rim Magjanov

Keyword(s):

Quality Of Life ◽

Botulinum Toxin ◽

Cervical Dystonia ◽

Affective Disorders

Download Full-text

Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital

Arquivos de Neuro-Psiquiatria ◽

10.1590/s0004-282x2011000700010 ◽

2011 ◽

Vol 69 (6) ◽

pp. 900-904 ◽

Cited By ~ 9

Author(s):

Mariana Ribeiro Queiroz ◽

Hsin Fen Chien ◽

Egberto Reis Barbosa

Keyword(s):

Quality Of Life ◽

Botulinum Toxin ◽

Cervical Dystonia ◽

Rating Scale ◽

Short Form ◽

Tertiary Care ◽

Residual Effect ◽

Care Hospital ◽

Sf 36

OBJECTIVE: The purpose of this study was to evaluate quality of life (QoL) in a Brazilian population of individuals with cervical dystonia (CD) without effect of botulinum toxin (BTx) or with only residual effect of BTx, and identify possible physical and social aspects that affect their QoL. METHOD: Sixty five out of sixty seven consecutive patients with CD were assessed with two instruments: Short-form Health Survey with 36 questions (SF-36) and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). RESULTS: Severity of CD (TWSTRS) correlated moderately with two SF-36 subscale: role-physical (r= -0.42) and body pain (r= -0.43). Women also scored worse in two subscale of SF-36: vitality (p<0.05) and mental-health (p<0.005). CONCLUSION: Severity of CD and gender (female) were the main factors related to a worse QoL perception. These findings may help health professionals to predict which characteristics could lead to worse QoL, and therefore, better target their interventions to lessen the burden caused by CD.

Download Full-text

Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis

International Journal of MS Care ◽

10.7224/1537-2073.2012-031 ◽

2013 ◽

Vol 15 (2) ◽

pp. 66-72 ◽

Cited By ~ 10

Author(s):

Gael J. Yonnet ◽

Anette S. Fjeldstad ◽

Noel G. Carlson ◽

John W. Rose

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Botulinum Toxin ◽

Urinary Tract ◽

Detrusor Overactivity ◽

Anticholinergic Drugs ◽

Neurogenic Detrusor Overactivity ◽

Botulinum Toxin Therapy ◽

Tract Infections

Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies used to treat them. Treatments for neurogenic detrusor overactivity (NDO) have consisted mainly of administration of anticholinergic drugs, which have been shown to provide suboptimal clinical benefits and be poorly tolerated. The US Food and Drug Administration (FDA) approval of intravesicular botulinum toxin therapy provides a second-line option for MS patients with NDO not responsive to anticholinergic drugs. We performed a review of key literature pertaining to the intravesicular application of botulinum toxin. In the management of NDO, administration of intravesicular botulinum toxin using clean intermittent catheterization decreases the incidence of urinary tract infections, promotes urinary continence, and improves quality of life for 9 months after a single injection; moreover, those benefits are maintained with repeated injections over time.

Download Full-text